Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | TACR1 | P25103 | 5/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.41 |
| ▸ | MC4R | P32245 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25479918 | 0.91 | LMNA (0.47) | MAPK1KDM4EMEN1KMT2APKM | |
| SCHEMBL25479491 | 0.90 | PKM (0.55) | MAPK1KDM4EMEN1KMT2APKM | |
| SCHEMBL25478844 | 0.86 | L3MBTL1 (0.40) | MAPK1TACR1MEN1KMT2ASIGMAR1 | |
| SCHEMBL25628656 | 0.85 | L3MBTL1 (0.36) | MAPK1MEN1KMT2A | |
| SCHEMBL25613596 | 0.82 | TACR1 (0.41) | TACR1KDM4EMEN1KMT2ASIGMAR1 | |
| SCHEMBL25479084 | 0.82 | ALDH1A1 (0.36) | MAPK1TACR1KDM4EMEN1KMT2A | |
| SCHEMBL25492871 | 0.82 | MAPK1 (0.42) | MAPK1KDM4EKMT2ASIGMAR1PKM | |
| SCHEMBL25478121 | 0.81 | L3MBTL1 (0.39) | MAPK1KDM4EMEN1KMT2APKM | |
| SCHEMBL25478816 | 0.81 | MAPK1 (0.35) | MAPK1KMT2APKM | |
| SCHEMBL25478777 | 0.80 | HTR7 (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159527-A1 | COMPOUNDS AS BCL-2 INHIBITORS | FOCHON BIOSCIENCES, LTD. (CN) | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159527-A1 | COMPOUNDS AS BCL-2 INHIBITORS | BCL2, BCL2L2, BCL2L1 | MAPK1 2612/4885TACR1 4609/4885KDM4E 2788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.